Cell and Gene Therapy Is Fueling Growth in the Hemophilia Treatment Market

 

The global Hemophilia Treatment Market is estimated to be valued at US$ 15,197.8 Mn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Hemophilia is a rare genetic bleeding disorder that causes prolonged or spontaneous bleeding from minor cuts or bruises, bleeding from the gums, internal bleeding in muscles and joints. Treatment products such as recombinant and plasma-derived coagulation factor concentrates, desmopressin, and antifibrinolytics are being used to treat hemophilia. Advances in cell and gene therapies are offering new hope for curative treatment options that can potentially eliminate or reduce invasive treatments over the lifetime of people with hemophilia.

Market Overview
Hemophilia treatment involves replacement of clotting factors which are deficient or missing in the blood of hemophilic patients. The advent of new therapeutic approaches such as gene therapy and increase in priority medication programs designed to improve patient outcomes are driving the hemophilia treatment market.

Market key trends
The emergence of novel biologics through advanced gene therapy and gene editing techniques. Gene therapy involves delivering functional copies of the missing or faulty gene that causes hemophilia into the patient’s cells and tissues. These therapies aim to restore stable levels of the missing coagulation factor with a single treatment and eliminate the need for repeated intravenous infusions. Additionally, such curative therapies could potentially be affordable for patients in low and middle-income countries and expand access to care. This is expected to revolutionize the treatment paradigm in hemophilia over the coming decade.
Segment Analysis
The global hemophilia treatment market is segmented based on product, therapy, disease, and end user. By product, the market is segmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, and desmopressin. The recombinant coagulation factor concentrates segment dominated the market in 2022 due to the advantages it offers over plasma-derived coagulation factor concentrates, including low risk of infection transmission and consistent quality and safety. By therapy, the market is divided into on-demand and prophylaxis. Prophylaxis therapy dominated the market in 2022 as it helps prevent prolonged bleeding episodes and maintain a more normal lifestyle when taken regularly. By disease, the market covers hemophilia A and hemophilia B. Hemophilia A accounted for the largest share of the market in 2022 due to its high prevalence. By end user, the market is bifurcated into home care settings and hospitals.

Key Takeaways
The global hemophilia treatment market is expected to witness high growth, exhibiting CAGR of 6.3% over the forecast period, due to increasing prevalence of hemophilia disorders and rising adoption of prophylaxis treatment.

Regional analysis - North America dominated the global hemophilia treatment market in 2022 and is expected to remain the leading region during the forecast period owing to the presence of developed healthcare infrastructure and favorable reimbursement policies. Asia Pacific is anticipated to witness the fastest growth during the forecast period supported by growing awareness about hemophilia disorders, increasing healthcare expenditure, and rising geriatric population.

Key players analysis - Key players operating in the hemophilia treatment market are Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, and F. Hoffmann-La Roche AG. Takeda Pharmaceutical Co., Ltd. is one of the leading players dominating the market due to its wide product portfolio of hemophilia treatment options.

Comments

Post a Comment

Popular posts from this blog

Unveiling Health Secrets: Exploring the Potential of Blood-Based Biomarkers

Image
  The human body is a complex and intricate system, often harboring subtle signs of its inner workings. One of the most promising avenues for unlocking these secrets lies within our bloodstream – a treasure trove of information encoded in the form of blood-based biomarkers. These biomarkers, measurable indicators present in the blood, hold the potential to revolutionize healthcare by providing early detection, accurate diagnosis, and personalized treatment approaches. Blood-based biomarkers encompass a wide range of molecules – from proteins and nucleic acids to metabolites and even circulating cells. Researchers have been diligently working to identify specific biomarkers associated with various diseases and conditions. For instance, elevated levels of certain proteins might point to cardiovascular diseases, while specific genetic material could indicate the presence of cancer. By analyzing these biomarkers, clinicians gain valuable insights into an individual's health status, en...
Read more

Revolutionizing Biology: Advancements in Single Cell Analysis Techniques

Image
  Single cell analysis has emerged as a groundbreaking technology that is revolutionizing the field of biology. Traditionally, biological studies were conducted on populations of cells, averaging out the heterogeneity present within them. However, the advent of single cell analysis has enabled scientists to delve into the complexity of individual cells, uncovering a wealth of previously inaccessible information. Advancements in single cell analysis techniques have paved the way for a deeper understanding of cellular heterogeneity, gene expression, and cellular behavior. One of the most remarkable techniques is single-cell RNA sequencing (scRNA-seq), which allows scientists to measure gene expression in individual cells. This breakthrough has led to the identification of rare cell types, understanding of cellular communication networks, and the discovery of novel biomarkers. Moreover, single cell imaging techniques, such as single cell fluorescence microscopy, have enabled research...
Read more

Medical Robots Market Poised to Grow Owing to Improving Healthcare Infrastructure

Image
 The Medical Robots Market is anticipated to witness robust growth due to rising healthcare spending across the globe. Medical robots are used to perform minimal invasive surgeries with greater accuracy and flexibility. Growing preference for Robot-Assisted Surgery (RAS) over conventional open surgeries due to benefits such as shorter recovery time and minimum operative scars has been augmenting demand for medical robots. Key functions include guiding and positioning surgical accessories like guide tubes in radiology and guiding catheter and wires in cardiology. With rising chronic disease prevalence associated with aging populations, the need for more surgical procedures is surging which requires precise action minimally invasive robotic systems can provide. The Global Medical Robots Market is estimated to be valued at US$ 11.47 Bn in 2024 and is expected to exhibit a CAGR of 16% over the forecast period 2023 to 2030. Key Takeaways: Key players operating in the Medical Robo...
Read more